Wyeth terminates license for SCOLR tech

Wyeth is terminating its license to use SCOLR's technology in products containing ibuprofen. SCOLR Pharma said it will continue the development of a 12-hour extended release ibuprofen product and would either seek out another large pharmaceutical company to partner with or develop the data alone to file an application with the FDA. The development and license agreement, signed December 21, 2005, provided Wyeth with global rights to use SCOLR's technology for all products containing ibuprofen. SCOLR has already received approximately $2.1 million in milestone and other payments from Wyeth, including more than $950,000 since January 1, 2007.

- read the release on the undoing of the deal

Suggested Articles

Galecto picked up $64 million to push its lead lung disease treatment toward an approval in Europe and fund midstage studies for its other programs.

The financing, which attracted support from Roche Venture Fund, sets Palladio up to test its vasopressin V2 receptor antagonist in a kidney disease.

A new atlas of 500,000 cardiac cells could help researchers better understand how a healthy heart operates—and what goes wrong in heart disease.